Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Investors would do well to avoid repeating the mistake of expecting moonshots in NVAX stock. The business may do better, but the stock won't.

Don't Bet on New Highs for Novavax Stock

Ocugen, Inc.

Vaxart

Select analysts foresee these coronavirus stocks rocketing higher by 246% to 355% over the next year.

3 COVID-19 Stocks With Monster Upside of Up to 355%, According to Wall Street

Novavax Inc (NASDAQ: NVAX) shares are trading significantly lower Tuesday. According to data from Benzinga Pro, Tuesday's trading volume is in line with Novavax's average trading volume over a 100-day period.

What's Going On With Novavax Shares Today?

After Covid-19 vaccine delivery and regulatory woes, there is finally more upside than downside risks with NVAX stock. The post Novavax Has More Upside Ahead, as Covid-19 Shots Hit the Market appeared first on InvestorPlace.

Novavax Has More Upside Ahead, as Covid-19 Shots Hit the Market

Novavax stock's foray in the adolescent Covid-19 vaccine market could pay dividends but investors should tread with caution at this time as risk remains. The post What to Make of Novavax's Adolescent Covid-19 Vaccine Move appeared first on InvestorPlace.

What to Make of Novavax's Adolescent Covid-19 Vaccine Move

Novavax delivered its first shipments to Canadian health authorities last week, and the news continues to help NVAX stock climb higher today. The post Novavax's First Canadian Shipments Are Boosting NVAX Stock appeared first on InvestorPlace.

Novavax's First Canadian Shipments Are Boosting NVAX Stock

Novavax is close to securing FDA approval for its Covid-19 vaccine yet NVAX stock is down since the end of January. What gives?

Novavax Stock Is Alluringly Attractive at This Stage

There are obvious reasons to be bearish on NVAX stock's price chart, but a word to the wise would include the use of this type of put spread. The post How to Approach Trading Downtrodden Novavax Today appeared first on InvestorPlace.

How to Approach Trading Downtrodden Novavax Today

Novavax (NVAX) seeks label expansion for its COVID-19 vaccine in adolescents aged 12-17 years in the European Union. Currently, the vaccine is authorized for use in adults.

Novavax (NVAX) Seeks EU Nod for COVID-19 Vaccine in Kids

If you're not otherwise engaged with NVAX stock, it's best to wait until the picture gets clearer on EUA approval. The post The Waiting Game Is Wearing Thin for Novavax Investors appeared first on InvestorPlace.

The Waiting Game Is Wearing Thin for Novavax Investors

Two outwardly positive developments for the company weren't enough to prevent a minor investor sell-off.

Why Novavax Stock Dipped On Thursday

The U.S. biotech has asked the European Medicines Agency to extend authorization of its Covid-19 shot to children aged 12 to 17

Novavax Asks EU Regulator to Clear Covid Vaccine For Adolescents

Novavax Inc. NVAX, -5.18% said Thursday it has submitted a request for an expanded authorization for its COVID-19 vaccine in the European Union for adolescents aged 12 to 17. "We are continuing to see spikes in COVID-19 across Europe and recognize the need to improve vaccination rates, particularly in the pediatric population," Chief Executive Stanley C.

Novavax seeks expanded authorization for COVID vaccine in Europe for adolescents aged 12 to 17

If granted, Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) would be the first protein-based option for adolescents aged 12-17 years in Europe GAITHERSBURG, Md. , March 31, 2022  /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced submission of its request to expand the conditional marketing authorization (CMA) of Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) in the European Union (EU) to adolescents aged 12 through 17 years.

Novavax Submits Request to Expand Conditional Marketing Authorization of COVID-19 Vaccine in the European Union to Adolescents (Ages 12-17)

Novavax (NVAX) reported earnings 30 days ago. What's next for the stock?

Why Is Novavax (NVAX) Down 5.9% Since Last Earnings Report?

Thermo Fisher Scientific

WILMINGTON, N.C.--(BUSINESS WIRE)--The clinical research business of Thermo Fisher Scientific has won a 2021 TOPRA Award for Regulatory Excellence.

Thermo Fisher Scientific's PPD Clinical Research Business Earns TOPRA Award for Regulatory Affairs Excellence in Supporting Novavax's COVID-19 Vaccine Approval

There's reason to believe things aren't going exactly as planned.

2 Reasons Why Novavax Investors Should Be Cautious

CRISPR Therapeutics

Teladoc

3 Ultra-Popular Stocks That Could Soar 120%, 51%, and 109%, Wall Street Says

BioNTech SE

Moderna

Investors appear to be concerned that Uncle Sam won't foot the bill for additional COVID-19 vaccine purchases.

Why Moderna, BioNTech, and Novavax Stocks Are Tumbling Today

Novavax Inc. NVAX, +1.58% said Friday that its experimental COVID-19 booster is being tested in a Phase 1/2 clinical trial sponsored by the National Institutes of Health. This study is evaluating Novavax's protein-based booster candidate in people who have already received the primary series of shots developed by BioNTech SE BNTX, +2.45% and Pfizer Inc. PFE, +0.77% , Johnson & Johnson JNJ, +0.52% , or Moderna Inc. MRNA, +0.53%.

Novavax's COVID-19 booster to be evaluated in NIH study

U.S. NIAID-sponsored trial will evaluate heterologous booster regimens, including NVX-CoV2373, after primary series with current FDA approved or emergency use authorized-vaccines NVX-CoV2373 will be evaluated in a head-to-head boosting trial in the United Arab Emirates to assess boosting options for a large number of the world's population that have previously been vaccinated with inactivated COVID-19 vaccine GAITHERSBURG, Md. , March 25, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that NVX-CoV2373, its protein-based COVID-19 vaccine, is included in two trials now underway to evaluate its vaccine's safety, immunogenicity, and reactogenicity as a booster amidst the ongoing COVID-19 pandemic.

Novavax Announces Participation in Two Booster Studies Using its COVID-19 Vaccine

Pfizer

The picture is improving for vaccine stocks. But there's still a lot of uncertainty.

Is It Time to Buy COVID-19 Vaccine Stocks Again?

Novavax's (NVAX) COVID-19 vaccine receives its first authorization for emergency use in adolescents aged 12 years and above in India.

Novavax's (NVAX) COVID Jab Gets EUA Nod for Kids in India

Argo Blockchain PLC

B. Riley Principal 150 Merger Corp

Enservco

Longeveron

Energy is understandably at the top of every investor's mind right now, but finding the best energy stocks requires careful consideration. The post 5 Cheap Energy Stocks Riding Oil Higher appeared first on InvestorPlace.

5 Cheap Energy Stocks Riding Oil Higher

While Novavax awaits the FDA approval, the frustration amongst investors is rising and a lot is on stake. Take a small position in NVAX stock.

News for Novavax Stock (NVAX)